Recruiting
Phase 1

OKI-219

Sponsor:

OnKure, Inc.

Code:

NCT06239467

Conditions

Advanced Cancer

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OKI-219

Fulvestrant

Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by OnKure, Inc. on 2025-03-06.